Drugs / JNJ-41443532
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01105780 | May → Aug 2010 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT01106469 | Feb → Jul 2010 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01230749 | Dec 2010 → Jun 2011 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-41443532 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01106469 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 2 antagonist” CHEMBL2204263 ↗ |
| Modality | Small molecule | — CHEMBL2204263 ↗ |
| Route | Oral | “by mouth on Day 1” NCT01105780 ↗ |
| Target | CCR2 | “C-C chemokine receptor type 2 antagonist” CHEMBL2204263 ↗ |